News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,459 Results
Type
Article (20036)
Company Profile (128)
Press Release (313295)
Multimedia
Podcasts (70)
Webinars (11)
Section
Business (105413)
Career Advice (879)
Deals (18541)
Drug Delivery (97)
Drug Development (50788)
Employer Resources (79)
FDA (7697)
Job Trends (7750)
News (185939)
Policy (17346)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (736)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (27845)
ALS (54)
Alzheimer's disease (639)
Antibody-drug conjugate (ADC) (88)
Approvals (7706)
Artificial intelligence (138)
Autoimmune disease (15)
Automation (5)
Bankruptcy (177)
Best Places to Work (5557)
BIOSECURE Act (13)
Biosimilars (95)
Biotechnology (57)
Bladder cancer (31)
Brain cancer (19)
Breast cancer (107)
Cancer (1036)
Cardiovascular disease (112)
Career advice (712)
Career pathing (20)
CAR-T (55)
Cell therapy (150)
Cervical cancer (5)
Clinical research (42674)
Collaboration (457)
Compensation (165)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (146)
Cystic fibrosis (58)
Data (1106)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (138)
Diagnostics (1813)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (80)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (59)
Earnings (39026)
Editorial (30)
Employer branding (10)
Employer resources (73)
Events (48564)
Executive appointments (434)
FDA (8272)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (310)
Gene editing (47)
Generative AI (18)
Gene therapy (144)
GLP-1 (590)
Government (1848)
Grass and pollen (2)
Guidances (18)
Healthcare (5907)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (83)
Indications (17)
Infectious disease (1180)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (55)
Interviews (116)
IPO (7372)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (21)
Layoffs (276)
Leadership (14)
Legal (4119)
Liver cancer (31)
Lung cancer (157)
Lymphoma (85)
Machine learning (2)
Management (30)
Manufacturing (198)
MASH (49)
Medical device (1966)
Medtech (1969)
Mergers & acquisitions (11422)
Metabolic disorders (490)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (49)
Neuropsychiatric disorders (20)
Neuroscience (949)
NextGen: Class of 2025 (2358)
Non-profit (906)
Northern California (1063)
Now hiring (20)
Obesity (307)
Opinion (190)
Ovarian cancer (33)
Pain (66)
Pancreatic cancer (35)
Parkinson's disease (86)
Partnered (11)
Patents (139)
Patient recruitment (45)
Peanut (16)
People (33448)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13362)
Phase II (18049)
Phase III (14504)
Pipeline (707)
Policy (117)
Postmarket research (1618)
Preclinical (4657)
Press Release (29)
Prostate cancer (59)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (242)
Real estate (3175)
Recruiting (29)
Regulatory (12526)
Reports (22)
Research institute (819)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (57)
Series B (32)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1018)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2009)
State (2)
Stomach cancer (9)
Supply chain (52)
Tariffs (24)
The Weekly (50)
United States (9993)
Vaccines (268)
Venture capitalists (27)
Weight loss (239)
Women's health (14)
Worklife (7)
Date
Today (46)
Last 7 days (236)
Last 30 days (1286)
Last 365 days (16804)
2025 (4678)
2024 (17670)
2023 (19642)
2022 (25867)
2021 (26644)
2020 (24874)
2019 (20069)
2018 (15590)
2017 (17255)
2016 (16202)
2015 (18801)
2014 (14788)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12741)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (24893)
Australia (3219)
California (2484)
Canada (1091)
China (320)
Colorado (95)
Connecticut (99)
Delaware (69)
Europe (51383)
Florida (433)
Georgia (54)
Idaho (16)
Illinois (243)
India (19)
Indiana (171)
Iowa (3)
Japan (115)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (360)
Massachusetts (2100)
Michigan (48)
Minnesota (136)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (16)
New Hampshire (8)
New Jersey (1015)
New Mexico (21)
New York (731)
North Carolina (493)
North Dakota (2)
Northern California (1063)
Ohio (81)
Oklahoma (5)
Oregon (21)
Pennsylvania (594)
Puerto Rico (11)
Rhode Island (16)
South America (607)
South Carolina (3)
Southern California (1018)
Tennessee (38)
Texas (327)
Utah (54)
Virginia (82)
Washington D.C. (43)
Washington State (215)
Wisconsin (20)
333,459 Results for "fosun pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Fosun Pharma Announces 2024 Annual Results
March 26, 2025
·
13 min read
Press Releases
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
February 26, 2025
·
5 min read
Press Releases
Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
February 17, 2025
·
7 min read
Press Releases
Fosun Pharma Announces 2024Q3 Financial Results
October 30, 2024
·
9 min read
Press Releases
Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation
February 17, 2025
·
7 min read
Press Releases
Fosun Pharma Announces 2024 Interim Results
August 28, 2024
·
13 min read
Pharm Country
Fosun Pharma USA Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
Fosun Pharma USA Inc. (“Fosun Pharma USA”) is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 - 11, 2024.
December 11, 2023
·
3 min read
Business
Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space
Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.
November 20, 2023
·
4 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Pharm Country
Fosun Pharma USA Announces Abstract to be Presented at IASLC 2023 North America Conference on Lung Cancer (NACLC)
Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).
November 28, 2023
·
5 min read
1 of 33,346
Next
